INFORMATION DISCLOSURE STATEMENT

Applicant	:	Balzarini et al.
App. No.	:	10/783,053
Filed	:	February 19, 2004
For	:	IDENTIFICATION OF COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS
Examiner	:	Unassigned
Group Art Unit	:	1645

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing one hundred thirty-six (136) references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 14, 2004

By: _____

Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

S:\DOCS\ESF\ESF-7880.DOC
060804

PATENT

Case Docket No. TRIPEP.058A
Date: July 14, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	:	Balzarini et al.
Appl. No.	:	10/783,053
Filed	:	February 19, 2004
For	:	IDENTIFICATION OF COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS
Examiner	:	Unassigned
Group Art Unit	:	1645

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 14, 2004
(Date)

Eric S. Furman, Ph.D., Reg. No. 45,664

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

(X) An Information Disclosure Statement.

(X) A PTO Form 1449 with one hundred thirty-six (136) references that are also enclosed.

(X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

(X) Return prepaid postcard.

Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

S:\DOCS\ESF\ESF-7883.DOC
060904

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.058A	APPLICATION NO. 10/783,053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Balzarini et al.	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE February 19, 2004	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	2002/0091086	07/11/02	Vahlne			
	2	2003/0166694	09/04/03	Dorsch et al.			
	3	2003/0232804	12/18/03	Pinto et al.			
	4	1,063,727	03/30/67	Morley			
	5	4,215,112	07/29/80	Goldstein et al.			
	6	4,528,133	07/09/85	Kasafirek et al.			
	7	4,612,337	09/16/86	Fox et al.			
	8	4,658,013	04/14/87	Morgan			
	9	4,818,540	04/04/89	Chinen et al.			
	10	4,857,538	08/15/89	Kashman et al.			
	11	4,950,647	08/21/90	Robins et al.			
	12	5,336,758	08/09/94	Berzofsky et al.			
	13	5,346,989	09/13/94	Vahlne et al.			
	14	5,449,752	09/12/95	Fuji et al.			
	15	5,470,951	11/28/95	Roberts			
	16	5,478,810	12/26/95	Stuber et al.			
	17	5,534,410	07/09/96	Tjian et al.			
	18	5,571,892	11/05/96	Fuji et al.			
	19	5,607,858	03/04/97	Stuber et al.			
	20	5,627,035	05/06/97	Vahlne et al.			
	21	5,710,128	01/20/98	Fuji et al.			
	22	5,744,368	04/28/98	Goldgaber et al.			
	23	5,770,620	06/23/98	Mjalli et al.			
	24	5,776,899	07/07/98	Matsumoto et al.			
	25	5,817,626	10/06/98	Findelis et al.			
	26	5,830,910	11/03/98	Mattson			
	27	5,830,994	11/03/98	D'Hinterland et al.			
	28	5,843,904	12/01/98	Bemis et al.			
	29	5,843,995	12/01/98	Rana et al.			

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.058A	APPLICATION NO. 10/783,053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Balzarini et al.	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE February 19, 2004	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	30	5,846,714	12/08/98	Haskill et al.			
	31	5,854,204	12/29/98	Findeis et al.			
	32	5,856,122	01/05/99	Read et al.			
	33	5,858,979	01/12/99	Kakkar et al.			
	34	5,872,210	02/16/99	Medabalimi			
	35	5,886,025	03/23/99	Pinney			
	36	5,932,550	08/03/99	Kato et al.			
	37	5,990,278	11/23/99	Hoffman et al.			
	38	6,184,210	02/06/01	Keanna et al.			
	39	6,242,416	06/05/01	Gilchrest et al.			
	40	6,258,932	07/10/01	Vahlne			
	41	6,455,670	09/24/02	Van der Spoel et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	42	H5[1993]-97789	04/20/93	JPO				
	43	2 668 488 A1	04/30/92	France				
	44	0 421 074 A1	04/01/91	Europe				
	45	0 894 855 A2	02/03/99	Europe				
	46	0 900 566 A1	03/10/99	Europe				
	47	WO 90/04390	05/01/90	WIPO				
	48	WO 92/20795	11/01/92	WIPO				
	49	WO 96/27386	09/01/96	WIPO				
	50	WO 96/28162	09/19/96	WIPO				
	51	WO 96/35714	11/01/96	WIPO				
	52	WO 98/09985	03/01/98	WIPO				
	53	WO 98/35062	08/01/98	WIPO				

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.058A	APPLICATION NO. 10/783,053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Balzarini et al.	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE February 19, 2004	GROUP 1645

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	54	WO 99/09056	02/25/99	WIPO				
	55	WO 99/09985	03/04/99	WIPO				
	56	WO 00/09158	02/01/00	WIPO				
	57	WO 01/10456	02/15/01	WIPO				
	58	WO 01/10457	02/15/01	WIPO				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	59	Abdel-Meguid et al., "An orally bioavailable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: Crystallographic and pharmacokinetic analysis," *Biochemistry*, 33(39):11671-11677 (1994).
	60	Allured et al., "Structure of exotoxin A of pseudomonas aeruginosa at 3.0- angstrom resolution," *Proc. Natl. Acad. Sci. USA*, 83(5):1320-1324 (1986).
	61	Armstrong et al., "A phase 1 study of chemically synthesized verotoxin (shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome," *J. Infectious Diseases*, J14 141:1042-1045 (1995).
	62	Armstrong and Peppler, "Maintenance of biological activity of pertussis toxin radioiodinated while bound to fetuin-agarose," *Infection & Immunity*, 55(5):1294-1299 (1987).
	63	Ashkenazi et al., "Safety and antitumor activity of recombinant soluble Apo2 ligand," *J. Clin. Invest.*, 104(2):155-162 (1999).
	64	Bai et al., "Characterization of the interaction of cryptophycin 1 with tubulin: binding in the vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction," Cancer Research, 56:4398-4406 (1996).
	65	Barger et al., "Tumor necrosis factors α and ß protect neurons against amyloid ß-peptide toxicity: Evidence for involvement of a κB-binding factor and attenuation of peroxide and Ca2+ accumulation," *Proc. Natl. Acad. Sci. USA* , 92:9328-9332 (1995).
	66	Bellini et al., *Chem. Abs.*, abstract 85988h, vol. 96 (1982).
	67	Boullin et al., *J. Physiol.*, 234:597-607 (1974).
	68	Brandhuber et a., "Mapping the enzymatic active site of pseudomonas aeruginosa exotoxin A," *Proteins*, 3(3):146-154 (1988).
	69	Choe et al., "The crystal structure of diphtheria toxin," *Nature*, 357(6375):216-222 (1992).
	70	Chothia and Janin, "Principles of protein-protein recognition," Nature, 256(5520):705-708 (1975).
	71	Conner et al., "Selective Proteasome Inhibition Attenuates Experimental Polyarthritis Via Inhibition of Nuclear Transcription Factor κB (NFκB) Activiation," Arthritis and Rheumatism, Abst. Suppl., 40(9) (1997).
	72	Conner et al., "Proteasome Inhibition Attentuates Nitric Oxide Synthase Expression, VCAM-1 Transcription and the Development of Chronic Colitis," *Journal of Pharmacology and Exp. Therpeutics*, 282(3):1615-1622 (1997).
	73	Durso et al., "The antimitotic tripeptide hemiasterlin," *Proc. Am. Assoc. Cancer Res. Annual Meeting*, Vol. 40, p. 286 (1999).

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.058A	APPLICATION NO. 10/783,053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Balzarini et al.	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE February 19, 2004	GROUP 1645

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	74	Erickson et al., "Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease," *Science*, 249(4968):527-533 (1990).
	75	Fields, ed., Third Edition, *Virology*, Lippencott-Raven pub., pp. 62, 70, 1513, 1645-46, 1778, 1882-83, 1886-89, 2047, 2113, 2221, and 2717 (1996).
	76	Finberg et al., "Prevention of HIV-1 Infection and Preservation of CD4 Function by the Binding CPFs to gp120," Science, 249:287-281 (1990).
	77	Gamble et al., "Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein," *Science*, 278:849-853 (1997).
	78	Glenner et al., "Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein," *Biochem. Biophys. Res. Commun.*, 120(3):885-890 (1984).
	79	Goobar-Larsson et al., "Molecules That Block Viral Infectivity and Methods of Use Thereof," **U.S. Patent Application** Serial No. 10/235,158, filed September 3, 2002.
	80	Grannelli-Piperno et al., "Efficient Interaction of HIV-1 with Purified Dendritic Cells via multiple chemokine Coreceptors," *J. Exp. Med.*, 184:2433-2438 (1996).
	81	Hall et al., "Substituted 4-hydroxyproline di- and tri-peptides as cytotoxic agents," *Amino Acids*, 16(1):79-89 (1999).
	82	Hartrodt et al., *Chem. Abs.*, abstract 187072j, vol. 99 (1983).
	83	Head et al., "Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits," *J. Biol. Chem.*, 266(6):3617-3621 (1991).
	84	Henderson et al., "Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: prostranslational modifications, proteolytic processing, and complete amino acid sequences," *Journal of Virology*, 66(4):1856-1865 (1992).
	85	Hewlitt et al., "Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin," *Infect. Immun.*, 40(3):1198-1203 (1983).
	86	Hilbich et al., "Substitutions of hydrophobic amino acids reduce the amyloidogenicity of alzheimer's disease ßA4 peptides," *J. Mol. Biol.*, 228:460-473 (1992).
	87	Huang et al., "The role of DNA in the mechanism of NFκB dimer formation: crystal structures of the dimerization domains of the p50 and p65 subunits," *Structure*, 5(11):1427-1436 (1997).
	88	Hwang et al., "Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1," *Science*, 253:71-74 (1991).
	89	Ito et al., "Isolation and some properties of A and B subunits of Vero toxin 2 and in vitro formation of hybrid toxins between subunits of Vero toxin 1 and Vero toxin 2 from Escherichia coli 0157:H7," *Microb. Pathog.*, 5(3):189-195 (1988).
	90	Jarrett and Lansbury, "Seeding 'One-dimensional crystallization' of amyloid: a pathogenic mechanism in alzheimer's disease and scrapie?" *Cell*, 73:1055-1058 (1993).
	91	Kowalski et al., "Functional regions of the envelope glycoprotein of human immunodeficiency virus type I," *Science*, 237:1351-1355 (1987).
	92	LaRosa et al., "Conserved Sequence and Structural Elements in the HIV-1 Principal Neutralizing Determinant," *Science*, 249: 932-935 (1989).
	93	Lassila et al., "A Role for Lys-His-Gly-NH2 in Avian and Murine B Cell Development," *Cell. Immun.*, 122:319-328 (1989).
	94	Latimer et al., "The N-terminal domain of IκBα Masks the nuclear localization signal(s) of p50 and c-Rel homodimers," *Mol. Cell. Biol.*, 18(5):2640 (1998).

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.058A	APPLICATION NO. 10/783,053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Balzarini et al.	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE February 19, 2004	GROUP 1645

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	95	Levine, "Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution," *Protein Science*, 2(3):404-410 (1993).
	96	Lingwood, "Role of verotoxin receptors in pathogenesis," *Trends in Microbiology*, 4(4):147-153 (1996).
	97	Lobet et al., "Site-specific alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin," *J. Exp. Med.*, 177(1):79-87 (1993).
	98	Loosmore et al., "Characterization of pertussis toxin analogs containing mutations in B-oligomer subunits," *Infect. Immun.*, 61(6):2316-2324 (1993).
	99	Louis et al., "Hydrophilic peptides derived from the transframe region of Ga-Pol inhibit the HIV-1 protease," *Biochemistry*, 37(8):2105-2110 (1998).
	100	Maldonado et al., "Experimental chemotherapy with combinations of erogosterol biosynthesis inhibitors in murine models of chagas' disease," *Antimicrobial Agents and Chemotherapy*, 37(6):1353-1359 (1993).
	101	Malek et al., "IκBα Functions through direct contacts with the nuclear localization signals and the DNA binding sequences of NF-αB," *J. Biol. Chem.*, 273(39):25427-25435 (1998).
	102	Martin, "Fast-acting slow viruses," Nature, 345:572-527 (1990).
	103	Masters et al., "Amyloid plaque core protein in Alzheimer disease and Down syndrome," Proc. Natl. Acad. Sci. USA, 82(12):4245-4249 (1985).
	104	Matthies et al., *Chem. Abs.*, abstract 204450k, vol. 101 (1984).
	105	Meek et al., "Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues," Nature, 343:90-92 (1990).
	106	Memar et al., "Antiviral Agents in Dermatology; Current Status and Future Prospects," *Int. J. of Derm.*, 34(9):597-606 (1995).
	107	Merritt et al., "Surprising leads for a cholera toxin receptor-binding antagonist: crystallographic studies of CTB mutants," *Structure*, 3(6):561-570 (1995).
	108	Miller et al., "Antiviral activity of carbobenzoxy Di- and Tripeptides on measles virus," *Applied Microbiology*, 16(10):1489-1496 (1968).
	109	Monks et al., "Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines," *J. National Cancer Institute*, 83(11):757-766 (1991).
	110	Moore et al., "In vivo depression of lymphocyte traffic in sheep by VIP and HIV (AIDS)-related peptides," *Immunopharmacology*, 16:181-189 (1988).
	111	Mukaida et al., "Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-κB and regulation of cytokine production/action through $ß_2$ integrin in vivo," *J. of Leukocyte Biology*, 59(2): 145-151 (1996).
	112	Nicolaides et al., *J. Med. Chem.*, 11:74-79 (1968).
	113	Niedrig et al., "Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein derived peptides," *J. of Gen. Vir.*, 75:1469-1474 (1994).
	114	Owellen et al., "Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class," *Cancer Res.*, 36(4):1499 (1976).
	115	Palker et al., "Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides," *Proc. Natl. Acad. Sci.* USA, 85(6):1932-1936 (1988).
	116	Prusiner, "Some speculations about prions, amyloid, and Alzheimer's disease," *N. Engl. J. Med.*, 310(10):661-663 (1984).

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.058A	APPLICATION NO. 10/783,053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Balzarini et al.	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE February 19, 2004	GROUP 1645

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	117	Prusiner, "Molecular biology of prion diseases," *Science*, 252(5012):1515-1522 (1991).
	118	Rao et al., "3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin," *J. Biol. Chem.*, 269(5):3132-3134 (1994).
	119	Richards, "Inhibition of the aspartic proteinase from HIV-2," *FEBS Letters*, 253(1,2):214-216 (1989).
	120	Rydon and Smith, ***Chem. Abs.***, Abstract 46056c, vol. 51 (1957).
	121	Sawada et al., "Identification of the fragment photoaffinity-labeled with azidodansyl-rhizoxin as Met-363-Lys0379 on beta-tubulin," *Biochem. Pharmacol.*, 45(7):1387-1394 (1993).
	122	Sheha et al., "Synthesis of di-and tripeptide analogues containing α-ketoamide as a new core structure for inhibition of HIV-1 protease," *Eur. J. Med. Chem.*, 35(10):887-894 (2000).
	123	SIGMA, **Peptide and Amino Acid Catalog**, p. 27 and p. 70, Copyright 1995-96.
	124	Sixma et al., "Comparison of the B-pentamers of heat-labile enteroxtoxin and verotoxin-1: two structures with remarkable similarity and dissimilarity," *Biochemistry*, 32(1):191-198 (1993).
	125	Sixma et al., "Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin," *J. Mol. Biol.*, 230(3):890-918 (1993).
	126	Sheiman et al., *Chem. Abs.*, abstract 43238a, vol. 102 (1985).
	127	Smith et al., "Blocking HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen," *Science*, 238:1704-1707 (1987).
	128	Srivastava et al., "HIV-1 Gag shares a signature motif with annexin (Anx7), which is required for virus replication," *Proc. Natl. Acad. Sci.* USA, 96:2704-2709 (1999).
	129	Stein et al., "Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli," *Nature*, 355:748-750 (1992).
	130	Su, Jin, "Effect of the Tri-peptide Glycyl-Prolyl-Glycine Amide on HIV-1 Replication," Karolinska Institutet, Department of Microbiology, Pathology and Immunology, Division of Clinical Virology, Huddinge University, Sweden, 2000.
	131	Su et al., "The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1," *J. of Human Virol.*, 4(1):1-7 (2001).
	132	Su et al., "The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication," *J. of Human Virol.*, 4(1):8-15 (2001).
	133	Vahlne, "Protein Polymerization Inhibitors and Methods of Use Thereof," **U.S. Patent Application** Serial No. 10/072,783, filed February 8, 2002.
	134	Van der Spoel et al., "Tripeptide Amides that Block Viral Infectivity and Methods of Use Thereof," **U.S. Patent Application** Serial No. 09/938,806 filed August 24, 2001.
	135	Van der Spoel et al., "Pentamer Peptide Amid, ALGPGNH2, Which Inhibits Viral Infectivity and Methods of Use Thereof," **.S. Patent Application** Serial No. 10/217,933, filed August 12, 2002.
	136	Weber, "Blocks on the viral exit," *Nature*, 345:573-574 (1990).

S:\DOCS\ESF\ESF-7941.DOC
062404

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.